Maria Ascencion Globisch

Mrs. Maria Ascencion Globisch

Uppsala University, Uppsala, Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in eLife
Verified
Journal Article
Open access
FOFabrizio Orsenigo
Fabrizio Orsenigo
LCLei Liu Conze
Lei Liu Conze
SJSuvi Jauhiainen
Suvi Jauhiainen
MCMonica Corada
Monica Corada
FLFrancesca Lazzaroni
Francesca Lazzaroni
EDElisabetta Dejana
Elisabetta Dejana
Cerebral cavernous malformation (CCM) is a rare neurovascular disease that is characterized by enlarged and irregular blood vessels that often lead to cerebral hemorrhage. Loss-of-function mutations to any of three genes results in CCM lesion formation; namely, KRIT1, CCM2, and PDCD10 (CCM3). Here, we report for the first time in-depth single-cell RNA sequencing, combined with spatial transcriptomics and immunohistochemistry, to comprehensively characterize subclasses of brain endothelial cells (ECs) under both normal conditions and after deletion of Pdcd10 (Ccm3) in a mouse model of CCM. Integrated single-cell analysis identifies arterial ECs as refractory to CCM transformation. Conversely, a subset of angiogenic venous capillary ECs and respective resident endothelial progenitors appear to be at the origin of CCM lesions. These data are relevant for the understanding of the plasticity of the brain vascular system and provide novel insights into the molecular basis of CCM disease at the single cell level.

1 April 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
JOJoppe Oldenburg
Joppe Oldenburg
MMMatteo Malinverno
Matteo Malinverno
MGMaria Ascencion Globisch
Maria Ascencion Globisch
CMClaudio Maderna
Claudio Maderna
MCMonica Corada
Monica Corada
PMPeetra Ulrica Magnusson
Peetra Ulrica Magnusson
Background and Purpose: Cerebral cavernous malformations (CCM) present as mulberry-like malformations of the microvasculature of the central nervous system. Current medical treatment of CCM lesions is limited to surgical removal of the vascular malformations. It is, therefore, important to identify therapeutic drug treatments for patients with CCM. Propranolol has shown great benefit in the treatment of infantile hemangioma. In addition, patients with CCM who receive propranolol have demonstrated a reduction of their lesions. Our investigation set out to provide preclinical data to support propranolol as a therapeutic treatment. Methods: An inducible endothelial-specific Ccm3 knockout murine model (CCM3 iECKO ) was used, with assessment of lesion quantity and size following oral treatment with propranolol. Scanning and transmission electron microscopy were used to characterize the CCM3 iECKO lesions and the effects of propranolol on the disease. Immunofluorescent imaging was used to investigate pericyte coverage in the propranolol-treated CCM3 iECKO mice. Results: With propranolol treatment, the lesion quantity, size, and volume decreased in both the brain and retina in the CCM3 iECKO model. Novel characteristics of the CCM3 iECKO lesions were discovered using electron microscopy, including plasmalemmal pits and thickening of the endothelial-pericyte basal membrane. These characteristics were absent with propranolol treatment. Pericyte coverage of the CCM3 iECKO lesions increased after propranolol treatment, and vascular leakage was reduced. Conclusions: This study supports the concept that propranolol can be used to reduce and stabilize vascular lesions and can, therefore, be suggested as a pharmaceutical treatment for CCM.

25 March 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
AYAnthony C. Y. Yau
Anthony C. Y. Yau
MGMaria Ascencion Globisch
Maria Ascencion Globisch
FOFavour Chinyere Onyeogaziri
Favour Chinyere Onyeogaziri
LCLei L. Conze
Lei L. Conze
RSRoss Smith
Ross Smith
PMPeetra Ulrica Magnusson
Peetra Ulrica Magnusson
Cerebral Cavernous Malformation (CCM) is a brain vascular disease with various neurological symptoms. In this study, we describe the inflammatory profile in CCM and show for the first time the formation of neutrophil extracellular traps (NETs) in rodents and humans with CCM. Through RNA-seq analysis of cerebellum endothelial cells from wild-type mice and mice with an endothelial cell-specific ablation of the Ccm3 gene (Ccm3iECKO), we show that endothelial cells from Ccm3iECKO mice have an increased expression of inflammation-related genes. These genes encode proinflammatory cytokines and chemokines, as well as adhesion molecules, which promote recruitment of inflammatory and immune cells. Similarly, immunoassays showed elevated levels of these cytokines and chemokines in the cerebellum of the Ccm3iECKO mice. Consistently, both flow cytometry and immunofluorescence analysis showed infiltration of different subsets of leukocytes into the CCM lesions. Neutrophils, which are known to fight against infection through different strategies, including the formation of NETs, represented the leukocyte subset within the most pronounced increase in CCM. Here, we detected elevated levels of NETs in the blood and the deposition of NETs in the cerebral cavernomas of Ccm3iECKO mice. Degradation of NETs by DNase I treatment improved the vascular barrier. The deposition of NETs in the cavernomas of patients with CCM confirms the clinical relevance of NETs in CCM.

1 February 2017 in Developmental Biology
Verified
Journal Article
Closed access
DKDoreswamy Kenchegowda
Doreswamy Kenchegowda
BNBryony Natale
Bryony Natale
MGMaria Ascencion Globisch
Maria Ascencion Globisch
DNDavid Natale
David Natale
SFSteven A. Fisher
Steven A. Fisher

24 August 2020 in Development
Verified
Journal Article
Open access
PDF file
ACAzzurra Cottarelli
Azzurra Cottarelli
MCMonica Corada
Monica Corada
GBGalina V Beznoussenko
Galina V Beznoussenko
Alexandre MironovAlexandre Mironov
Alexandre Mironov
MGMaria Ascencion Globisch
Maria Ascencion Globisch
EDElisabetta Dejana
Elisabetta Dejana
Central nervous system (CNS) blood vessels contain a functional blood-brain barrier (BBB) that is necessary for neuronal survival and activity. Although Wnt/β-catenin signaling is essential for BBB development, its downstream targets within the neurovasculature remain poorly understood. To identify targets of Wnt/β-catenin signaling underlying BBB maturation, we performed a microarray analysis that identified Fgfbp1 as a novel Wnt/β-catenin-regulated gene in mouse brain endothelial cells (mBECs). Fgfbp1 is expressed in the CNS endothelium and secreted into the vascular basement membrane during BBB formation. Endothelial genetic ablation of Fgfbp1 results in transient hypervascularization but delays BBB maturation in specific CNS regions as evidenced by both upregulation of Plvap and increased tracer leakage across the neurovasculature due to reduced Wnt/β-catenin activity. In addition, collagen IV deposition in the vascular basement membrane is reduced in mutant mice, leading to defective endothelial cell-pericyte interactions. Fgfbp1 is required cell-autonomously in mBECs to concentrate Wnt ligands near cell junctions and promote maturation of their barrier properties in vitro. Thus, Fgfbp1 is a critical extracellular matrix protein during BBB maturation that regulates cell-cell interactions and Wnt/β-catenin activity.

17 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BNBryony V. Natale
Bryony V. Natale
CSChristina Schweitzer
Christina Schweitzer
MHMartha Hughes
Martha Hughes
MGMaria Ascencion Globisch
Maria Ascencion Globisch
RKRamie Kotadia
Ramie Kotadia
DNDavid Natale
David Natale
Trophoblast stem (TS) cells in the mouse derive from the polar trophectoderm of the blastocyst and persist through early gestation (to E8.5) to support placental development. Further development and growth is proposed to rely on layer-restricted progenitor cells. Stem cell antigen (Sca) -1 is a member of the Ly6 gene family and a known marker of stem cells in both hematopoietic and non-hematopoietic mouse tissues. Having identified that Sca-1 mRNA was highly expressed in mouse TS cells in culture, we found that it was also expressed in a subset of trophoblast within the chorion and labyrinth layer of the mouse placenta. Isolation and in vitro culture of Sca-1+ trophoblast cells from both differentiated TS cell cultures and dissected mouse placentae resulted in proliferating colonies that expressed known markers of TS cells. Furthermore, these cells could be stimulated to differentiate and expressed markers of both junctional zone and labyrinth trophoblast subtypes in a manner comparable to established mouse TS cell lines. Our results suggest that we have identified a subpopulation of TS cell-like cells that persist in the mid- to late- gestation mouse placenta as well as a cell surface protein that can be used to identify and isolate these cells.